Phase 3 frontMIND trial shows tafasitamab-lenalidomide plus R-CHOP significantly improves progression-free survival in high-risk DLBCL/HGBL, supporting global regulatory submissions.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
Incyte reported positive results from the pivotal Phase 3 frontMIND trial (NCT04824092) showing that adding tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide to R-CHOP significantly improved progression-free survival (PFS) in adults with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The findings were presented during the Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress and published in The Lancet.
Trial Design and Patient Population
The randomized, double-blind, placebo-controlled study enrolled 899 adults aged 18–80 years with newly diagnosed DLBCL or HGBL. Eligible patients had an International Prognostic Index (IPI) score of 3–5 or an age-adjusted IPI score of 2–3 in patients aged 60 years or younger. The study compared tafasitamab and lenalidomide plus R-CHOP with standard R-CHOP. Tafasitamab is an Fc-engineered CD19-targeting monoclonal antibody designed to enhance immune-mediated killing of malignant B cells.
Efficacy: 25% Risk Reduction in PFS
After a median follow-up of 35.2 months, Tafa-Len-R-CHOP reduced the risk of disease progression or death by 25% compared with R-CHOP alone (HR 0.75; P=0.0194). Progression-free survival improved by 8.2 percentage points at two years (71.1% vs 62.9%) and by 6.6 points at three years (67.3% vs 60.7%). The combination also significantly improved event-free survival (HR 0.79; P=0.0260). Interim overall survival analysis showed a favorable trend (HR 0.85), although statistical significance was not reached at the time of analysis.
Clinical benefit remained consistent across prespecified subgroups, including centrally confirmed lymphoma subtypes and both activated B-cell-like (ABC) and germinal center B-cell-like (GCB) molecular subtypes. The regimen also achieved higher minimal residual disease negativity rates than R-CHOP alone (81.3% vs 66.7%).
Safety and Tolerability
The safety profile was generally consistent with the known effects of the individual therapies. The most common treatment-emergent adverse events with Tafa-Len-R-CHOP were neutropenia, anemia, and peripheral neuropathy. Grade ≥3 adverse events occurred more frequently with the combination than with R-CHOP alone (86.7% vs 76.1%). Despite this, treatment discontinuation rates were similar between arms (5.2% vs 5.4%), underscoring regimen manageability in clinical practice. Investigators noted that the added safety burden was manageable and did not interfere with administration of the R-CHOP backbone.
Clinical Implications
Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-Stage Development at Incyte, said the findings reinforce the potential of Tafa-Len-R-CHOP to change the treatment landscape for patients with DLBCL and HGBL.
Principal investigator Georg Lenz, M.D., of University Hospital Münster, emphasized that preventing relapse remains a central goal in frontline lymphoma treatment and noted that the addition of tafasitamab and lenalidomide improved outcomes without compromising delivery of R-CHOP.
Path Toward Approval
The frontMIND findings support planned global regulatory submissions for tafasitamab and lenalidomide inope combination with R-CHOP for previously untreated DLBCL and HGBL. If approved, Tafa-Len-R-CHOP could become a new first-line standard of care for patients at high risk of relapse and disease progression—representing the first frontline advance in decades for aggressive B-cell lymphomas.
Reference
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.